Financial Performance - Enliven reported a net loss of $25.3 million for Q2 2025, up from a net loss of $20.0 million in Q2 2024[8][13]. - General and administrative (G&A) expenses for Q2 2025 were $7.1 million, compared to $5.8 million in Q2 2024[8][13]. - Research and development (R&D) expenses for Q2 2025 were $21.5 million, an increase from $18.8 million in Q2 2024[8][13]. - Total operating expenses for Q2 2025 were $28.6 million, compared to $24.6 million in Q2 2024[8][13]. Cash Position - The company has a strong cash position of $491 million, expected to provide a cash runway into the first half of 2029[1][8]. - The recent public offering generated gross proceeds of approximately $230 million, strengthening the company's balance sheet[2]. Clinical Development - Enliven Therapeutics reported a cumulative major molecular response (MMR) rate of 47% for ELVN-001, with 32% of patients achieving MMR by 24 weeks[1][3]. - The achieved MMR rate of 32% for ELVN-001 compares favorably to historical data from less heavily pretreated patients receiving asciminib, which showed MMR rates of 24%[3]. - ELVN-001 demonstrated a favorable safety and tolerability profile across all dose levels[1][3]. - The company plans to initiate a Phase 3 pivotal trial for ELVN-001 in 2026[4].
IMARA(IMRA) - 2025 Q2 - Quarterly Results